Key facts
- Neurovalens’s last known valuation is $15.5M (Jun 2021).
- It has raised $28.0M; the latest was Later Stage VC ($8.1M) in Aug 2025.
- Notable investors include MedTech Innovator, StartX (US), Texas Medical Center, British Business Bank, Government of UK — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Neurovalens
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurovalens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurovalens
Developer of non-invasive neurostimulation products designed to treat global health epidemics. The company's medical device technology offers transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus to allow for alterations in autonomic function, circadian regulation and neuro-metabolic influence, enabling healthcare providers to provide drug-free options and improve patients' health outcomes.
- Sector
- Healthcare
- HQ
- Belfast, United Kingdom
- Founded
- 2013
- Employees
- 25
- Website
- neurovalens.com/
- Ownership
- Privately Held (backing)
Neurovalens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurovalens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurovalens in its N-PORT filings yet. We sweep new filings monthly.